HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tamara Minko Selected Research

penetratin

2/2021Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin.
9/2018Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer.
2/2014A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts.
8/2013Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tamara Minko Research Topics

Disease

52Neoplasms (Cancer)
04/2024 - 08/2002
11Lung Neoplasms (Lung Cancer)
02/2021 - 09/2004
8Ovarian Neoplasms (Ovarian Cancer)
01/2023 - 01/2003
8Carcinoma (Carcinomatosis)
11/2013 - 08/2002
6Hypoxia (Hypoxemia)
02/2011 - 03/2003
3Neoplasm Metastasis (Metastasis)
07/2021 - 11/2010
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2021 - 12/2011
3Prostatic Neoplasms (Prostate Cancer)
02/2021 - 02/2014
3Necrosis
02/2010 - 01/2005
2COVID-19
01/2023 - 01/2021
2Breast Neoplasms (Breast Cancer)
02/2021 - 10/2018
2Lung Diseases (Lung Disease)
02/2021 - 12/2015
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
09/2018 - 08/2013
2Idiopathic Pulmonary Fibrosis
08/2017 - 06/2013
2Melanoma (Melanoma, Malignant)
04/2016 - 12/2014
2Drug-Related Side Effects and Adverse Reactions
12/2014 - 11/2006
2Colonic Neoplasms (Colon Cancer)
12/2005 - 01/2004
2Atherosclerosis
04/2004 - 02/2004
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2022
1Adenocarcinoma of Lung
02/2021
1Leukemia
02/2021
1Lymphoma (Lymphomas)
02/2021
1Cystic Fibrosis (Mucoviscidosis)
02/2021
1Respiratory Tract Diseases (Respiratory Tract Disease)
02/2021
1Pancreatic Neoplasms (Pancreatic Cancer)
10/2020
1Peripheral Nervous System Diseases (PNS Diseases)
10/2019
1Triple Negative Breast Neoplasms
10/2018

Drug/Important Bio-Agent (IBA)

19Peptides (Polypeptides)IBA
04/2024 - 06/2003
19Small Interfering RNA (siRNA)IBA
02/2024 - 07/2006
15Gonadotropin-Releasing Hormone (GnRH)FDA Link
07/2021 - 06/2003
15Doxorubicin (Adriamycin)FDA LinkGeneric
03/2014 - 01/2003
12Proteins (Proteins, Gene)FDA Link
01/2023 - 03/2003
11Liposomes (Liposome)IBA
09/2020 - 08/2006
9Messenger RNA (mRNA)IBA
01/2023 - 06/2010
9Paclitaxel (Taxol)FDA LinkGeneric
01/2022 - 11/2006
9Antisense OligonucleotidesIBA
02/2012 - 03/2004
7Dendrimers (Dendrons)IBA
11/2013 - 11/2006
5LigandsIBA
04/2024 - 01/2004
5Ethylene Glycol (Monoethylene Glycol)IBA
12/2011 - 08/2002
4Nucleic AcidsIBA
04/2024 - 11/2013
4LipidsIBA
07/2021 - 08/2007
4penetratinIBA
02/2021 - 08/2013
4LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA
01/2019 - 06/2003
4multidrug resistance-associated protein 1IBA
11/2013 - 09/2004
4PolymersIBA
11/2010 - 12/2005
3AntibodiesIBA
01/2023 - 01/2006
3Antineoplastic Agents (Antineoplastics)IBA
01/2017 - 07/2005
32- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
11/2010 - 08/2002
3CamptothecinIBA
11/2010 - 08/2002
3hydroxypropyl methacrylateIBA
02/2010 - 01/2003
3CaspasesIBA
06/2008 - 03/2004
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2008 - 03/2003
3ProdrugsIBA
11/2007 - 06/2006
2VaccinesIBA
01/2023 - 01/2021
2Monoclonal AntibodiesIBA
01/2023 - 01/2006
2DNA (Deoxyribonucleic Acid)IBA
01/2022 - 09/2018
2Gefitinib (Iressa)FDA Link
07/2021 - 01/2019
2Hormones (Hormone)IBA
07/2021 - 01/2017
2Cisplatin (Platino)FDA LinkGeneric
02/2021 - 12/2011
2Dinoprostone (PGE2)FDA Link
08/2017 - 06/2013
2Transcription Factors (Transcription Factor)IBA
02/2014 - 08/2013
2poly(propyleneimine)IBA
11/2013 - 01/2011
2Silicon Dioxide (Silica)FDA LinkGeneric
12/2011 - 12/2009
2Poly(amidoamine)IBA
01/2010 - 02/2009
2Hypoxia-Inducible Factor 1IBA
06/2008 - 11/2004
2human VEGFA proteinIBA
06/2006 - 03/2003
2Oxygen (Dioxygen)IBA
01/2005 - 03/2003
2Multidrug Resistance-Associated ProteinsIBA
11/2004 - 09/2004
2Cyclosporine (Ciclosporin)FDA LinkGeneric
04/2004 - 02/2004
1Cancer VaccinesIBA
01/2023
1mRNA VaccinesIBA
01/2023
1Nucleic Acid-Based VaccinesIBA
01/2023
1Single-Chain AntibodiesIBA
01/2023
1PlatinumIBA
01/2022
1Carboplatin (JM8)FDA LinkGeneric
01/2022
1Mechanistic Target of Rapamycin Complex 1IBA
01/2022
11- ethyl- 7- (2- methyl- 6- (1H- 1,2,4- triazol- 3- yl)pyridin- 3- yl)- 3,4- dihydropyrazino(2,3- b)pyrazin- 2(1H)- oneIBA
01/2022
1ErbB Receptors (EGF Receptor)IBA
07/2021
1Luteinizing Hormone (Lutropin)FDA LinkGeneric
07/2021
1RhodaminesIBA
07/2021
1Pemetrexed (MTA)FDA Link
02/2021
1Antiviral Agents (Antivirals)IBA
01/2021
1snake venom protein C activatorIBA
10/2020
1Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA
10/2020
1poly(lactide) (polylactic acid)IBA
10/2020
1Proteolysis Targeting ChimeraIBA
10/2020
1Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric
10/2020
1ARV-825IBA
10/2020
1glycolic acid (glycolate)IBA
10/2020
1Phosphatidylcholines (Phosphatidylcholine)IBA
09/2020
1osimertinibIBA
09/2020
1Progesterone Receptors (Progesterone Receptor)IBA
10/2018
1Estrogen ReceptorsIBA
10/2018
1human ERBB2 proteinIBA
10/2018
1ProstaglandinsIBA
08/2017

Therapy/Procedure

23Therapeutics
01/2023 - 11/2004
19Drug Therapy (Chemotherapy)
01/2022 - 01/2003
2Intravenous Injections
11/2013 - 05/2006
1Immunotherapy
10/2018
1Molecular Targeted Therapy
09/2018